Skip to main content
. 2004 Jun 1;4(7):1–98.

Table 2. Open TMS studies in major depression: patient characteristics, treatment parameters and comments.

      Medication Stimulus
intensity
Pulse
freq.(Hz)
Train
duration(s)
Number
of trains
Pulses per
session
Total
session
 
Study Treatment Age Resist Free Comment
Hoflich et al.
(1993)
Vertex
TMS
42.0 Yes No 105–130% MT 0.3 na na 250 10 One patient had slight improvement.
George et al.
(1995)
LDLPFC
rTMS
46.5 Yes 4/6 80% MT 20 2 20 800 5+ Two robust responders.
Grisaru et al.
(1995)
Motor
TMS
39.4 na No 2 T 0.017 3600 1 60 1 Outcome assessed after single session; 4 mild improvement, 1 worse, 5 no change.
Geller et al. (1997) LPFC and RPFC TMS 39.4 na No 2.5 T 0.033 900 1 30 1 Outcome assessed after single session; 3 immediate, lifeting of mood; 2 possible improvement; 1 worsening 4 no change.
Epstein et al. (1998) LDLPFC rTMS 40.0 Yes Yes 110% MT 10 5 10 250 5 Age < 65, 4 dropouts, rTMS resulted in HRSD < 10 in 50% of sample. 8/10 with previous favourable response to ECT responded to rTMS (HRSD < 10). Non-responders older than rTMS responders.
Figiel et al. (1998) LDLPFC rTMS 59.9 53/56 50/56 110% MT 10 5 10 500 5 Sample overlaps with Epistein study, but includes new sample≥65. Results calculated on 50 patients who completed study. Only 2.3% of ≥65 responded; 56% of those < 65 responded (< 60%HRSD reduction with maximal post score of 16). Only 2 of 8 patients (25%) with psychotic depression responded.
Feinsod et al. (1998) RDLPFC TMS 58.0 na 4/14 1 T, 0.1 ms 1 60 2 120 10 By CGI 6 of 14 (42.9%) MDD patients showed marked improvement.
Menkes et al. (1999) RF TMS 33.3 No No 100% MT 0.5 40 5 800 8 Included 6 healthy controls who had no change in HRSD score(mean 0.7).
Pridmore (1999) LDLPFC rTMS 57 Yes No 90–100% MT 10 5 20 1000 10–14 All 12 patients were dexamethasone test (DST) non-suppressors at baseline. 6 Of 12 normalized the DST after rTMS. These 6 had strong clinical improvement (MADRS decreased from 31 to 9; 70.0%)and maintained their response for at least 4 wk. The remaining 6 patients showed at best moderate improvement that was not sustained.
Pridmore et al. (1999) LDLPFC rTMS 52.5 Yes 5/24 90-100% MT 10 5 25 1250 12–14 Patients were characterized as melancholic by CORE criteria. Only 3 went on to receive ECT. In 19 of 24 episodes (79.2%) MADRS scores decreased by < 50%. The mean time from treatment to relapes was 20 wk.
Triggs et al. (1999) LDLPFC rTMS 52.0 9/10 Yes 80% MT 20 2 40 2000 10 5/10 had at least 50% redution in HRSD. Motor-evoked potnetial threshold decreased during treatment in 9/10.
Eschweiler et al.(2000) LDLPFC RTMS
(n = 2) RDLPFC TMS
(n = 2)
50.0 Unknown Unknown LDLPFC: 90–100% MT;
RDLPFC: 130% MT
LDLPFC 10%;
RDLPFC: 1
LDLPFC: 5–6.5;
RDLPFC: 50
LDLPFC: 20;
RLDPFC: 20
LDLPFC: 1000–1300;
RLDPFC: 1000
5–15 38% of patients were responders with CGI score indicating much or very much improved. Non-responters and patients who relapsed received RUL ECT after an average of 14.3 ± 153 d;12 of 16 responded to ECT. The inclued all 6 TMS responders. The 4 ECT non-responders did not respond to earlier TMS (p < 0.05).
Cohen et al. (unpubl. obs.) Bilateral TMS: LDLPFC rTMS and RDLPFC TMS 45 Yes No LDLPFC: 100% MT;
RLDPFC: 100% MT
LDLPFC: 20;
RDLPFC 1
LDLPFC: 1.5;
RLDPFC: 60
LDLPFC: 20;
RLDPFC: 2
LDPFC: 600;
RDLPFC: 120
5–10 4/10 (40%)patients showed a 50% reduction in HRSD scores, but change in CGI and self-ratings wwre slight. There was a trent for younger patients to have stronger therapeutic response.

Burt T, Lisanby SH, Sackeim HA. Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. International Journal of Neuropsychopharmacology 2002; 5(1):73-103; Subject to the copyright notice provided by Cambridge University Press, Reprinted with the permission of Cambridge University Press and the author (9)